23. May 2023 | Corporate News

Marinomed Biotech AG reports best first quarter in company history

  • Q1 revenues up 38% to new record of € 3.3 million thanks to broadband virus blocker Carragelose
  • Carragelose: Preparations for market entry in the USA and extension of use to allergic indications in full swing
  • Marinosolv: Full focus on commercialization of product candidates Tacrosolv and Budesolv
  • Financial outlook for full year 2023 confirmed

 

The full press release is available as download here:

Marinomed Biotech AG reports best first quarter in company history
(88 KB)